Cargando…

Current and Future Clinical Applications of ctDNA in Immuno-Oncology

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive opportunity to diagnose, characterize, and monitor the disease in individual cancer patients. ctDNA can reflect the actual tumor burden and specific genomic state of disease and thus might serve as a prognostic an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stadler, Julia-Christina, Belloum, Yassine, Deitert, Benjamin, Sementsov, Mark, Heidrich, Isabel, Gebhardt, Christoffer, Keller, Laura, Pantel, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397642/ https://www.ncbi.nlm.nih.gov/pubmed/34815256 http://dx.doi.org/10.1158/0008-5472.CAN-21-1718

Ejemplares similares

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
por: Keller, Laura, et al.
Publicado: (2020)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

Next-generation ctDNA-driven clinical trials in precision immuno-oncology
por: Aggarwal, Charu, et al.
Publicado: (2023)

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
por: Stadler, Julia-Christina, et al.
Publicado: (2023)

Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors
por: Heidrich, Isabel, et al.
Publicado: (2023)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Correction to: Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends
por: Posa, Alessandro, et al.
Publicado: (2023)

Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma
por: Geidel, Glenn, et al.
Publicado: (2022)

Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB
por: Fridland, Stanislav, et al.
Publicado: (2021)

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
por: Dao, Jonathan, et al.
Publicado: (2023)

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
por: Holmen Olofsson, Gitte, et al.
Publicado: (2020)

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
por: Zografos, Eleni, et al.
Publicado: (2022)

Current markers and their value in the era of immuno-oncology
por: von Rundstedt, Friedrich-Carl, et al.
Publicado: (2017)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook
por: Lianidou, Evi
Publicado: (2021)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Liquid biopsy: blood‐based analyses of circulating cell‐free DNA in xenografts
por: Heidrich, Isabel, et al.
Publicado: (2022)

ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
por: Neumann, Martin H.D., et al.
Publicado: (2018)

The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives
por: Sancho-Araiz, Aymara, et al.
Publicado: (2021)

Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
por: De Keukeleire, Stijn J., et al.
Publicado: (2021)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
por: Gilson, Pauline, et al.
Publicado: (2021)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Current clinical challenges and opportunities in oncologists' familiarity and understanding of immuno-oncology
por: Herrmann, Tara, et al.
Publicado: (2014)

SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
por: Belluomini, Lorenzo, et al.
Publicado: (2022)

Mevalonate Metabolism in Immuno-Oncology
por: Gruenbacher, Georg, et al.
Publicado: (2017)

Immuno-Oncology Essentials: An Overview
por: Hoffner, Brianna
Publicado: (2019)

Multiplex imaging in immuno-oncology
por: Zhao, Chen, et al.
Publicado: (2023)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7p9fre5vuk056sil7cg60tc2gj